OCM
HAE icon

Ovata Capital Management’s Haemonetics HAE Stock Holding History

Ovata Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,763
Closed -$158K – 116
2020
Q2 		$158K Buy
+1,763
New +$178K 0.05% 73

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ovata Capital Management's HAE Position: Q3 2020 in Review

Ovata Capital Management sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 1,763 shares — an estimated $158K sold.

Ovata Capital Management first reported a position in HAE in Q2 2020 and held it in 1 quarter. The position peaked at $158K in Q2 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

  • Ovata Capital Management reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
  • Ovata Capital Management sold 1,763 Haemonetics shares in Q3 2020, an estimated $158K.
  • Ovata Capital Management first reported a position in Haemonetics in Q2 2020 and held it in 1 quarter.
  • Ovata Capital Management's Haemonetics position peaked at $158K in Q2 2020.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Ovata Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.